The Different Stages of Menopause: How to Tell Where You Are (Peri, Meno, Post)
This is not a replacement for medical care and is intended exclusively for educational purposes. The content provided here does not constitute medical guidance. If you’re experiencing any of these symptoms, we strongly recommend you consult a qualified healthcare provider.
Irregular periods, disrupted sleep, unpredictable mood swings, and hot flashes that seem to arrive out of nowhere-these are the kinds of changes that send many women searching for answers about the different stages of menopause. The trouble is, menopause is often talked about as a single event, when in reality it is a multi-year biological process with distinct phases, each with its own hormonal signature and symptom pattern.
Understanding menopause stages matters because the right conversation with a specialist, the right lab tests, and the right symptom-management strategy all depend on knowing where you actually are in the transition. A woman in early perimenopause with occasional cycle changes needs a different approach than someone several years into postmenopause managing bone health. Clinical researchers have worked to standardize this picture: the Stages of Reproductive Aging Workshop + 10 (STRAW+10) framework, developed by reproductive endocrinology experts, gives clinicians and patients a shared language for describing where someone sits along the continuum (Harlow et al., J Clin Endocrinol Metab, 2012).
This guide walks through each recognized stage of the menopause transition, the signs associated with each one, and what current research says about symptoms, hormone changes, and long-term health considerations. It is intended to help you have a more informed conversation with a healthcare professional, not to replace one.
Ready to talk to
a specialist?
Skip the wait, the paperwork, and the referrals.
A certified specialist is ready to see you.
Mapping the Different Stages of Menopause: The STRAW+10 Framework
The STRAW+10 staging system organizes the menopause transition into a sequence of phases anchored to two key reference points: the final menstrual period (FMP) and the pattern of menstrual bleeding leading up to and following it (Harlow et al., J Clin Endocrinol Metab, 2012). Rather than treating menopause as a single date, this system recognizes that reproductive aging unfolds gradually, with hormone fluctuations that can begin years before periods actually stop and continue to shift for years afterward.
In broad terms, the framework groups the transition into three overarching phases, each with sub-stages:
- Perimenopause (the menopause transition) – further divided into early and late stages
- Menopause – the single point in time marking 12 months since the last period
- Postmenopause – further divided into early and late stages
Because hormone levels during this window can be erratic rather than steadily declining, a single blood test on a single day often cannot definitively confirm which stage someone is in. This is part of why clinicians tend to rely on a combination of menstrual history, symptom pattern, and-when useful-trends in hormone markers over time rather than one isolated lab value.
Stage 1: Early Perimenopause – What Are the Early Stages of Menopause?
For many women, the first noticeable sign is a subtle change in menstrual cycle length-cycles that were once predictable become slightly shorter or longer, often by seven days or more in either direction. This is generally considered the entry point into early perimenopause and is one of the most common answers to the question of what are the early stages of menopause actually like in practice.
Early perimenopause can begin in the mid-to-late 40s for many women, though timing varies considerably. Alongside cycle changes, women may notice:
- Occasional sleep disruption, even without obvious night sweats
- New or increased premenstrual mood sensitivity
- Mild, intermittent hot flashes
- Changes in breast tenderness or cycle-related bloating
- Subtle shifts in libido or vaginal comfort
Ovarian follicle activity is still relatively intact at this stage, but hormone production is beginning to fluctuate. Anti-Müllerian hormone (AMH), a marker produced by developing ovarian follicles, tends to decline progressively as the ovarian reserve diminishes, and research suggests tracking AMH trends over time may help estimate proximity to the broader transition-though it is not considered a standalone diagnostic test for pinpointing an individual’s exact stage (Nelson et al., Human Reproduction Update, 2023).
Stage 2: Late Perimenopause – When Change Accelerates
Late perimenopause is marked by more pronounced menstrual irregularity, including cycles that skip entirely for 60 days or longer. This stage tends to be shorter than early perimenopause but is often when symptoms become more noticeable and disruptive.
Common features of late perimenopause include:
- Extended gaps between periods
- More frequent and intense vasomotor symptoms (hot flashes and night sweats)
- More noticeable sleep disturbance
- Increased mood variability, including a measurably higher risk of depressive symptoms during this window compared with the premenopausal years (Badawy et al., Journal of Affective Disorders, 2024)
- Early changes in vaginal tissue comfort or urinary frequency
Follicle-stimulating hormone (FSH) levels tend to rise and become more variable during this stage as the ovaries respond less predictably to signaling from the brain. Because hormone levels fluctuate rather than decline in a straight line, many specialists find it more useful to interpret hormone testing alongside a detailed symptom and cycle history, rather than relying on a single lab draw.
Stage 3: Menopause Itself – The One Definitive Marker
Menopause, technically, is not a phase at all-it is a single point in time, defined retrospectively as the date marking 12 consecutive months without a menstrual period, with no other biological explanation for the absence of periods (NAMS 2022 Position Statement, Menopause, 2022; Stuenkel et al., J Clin Endocrinol Metab, 2015). In the United States, this milestone occurs, on average, around age 51 to 52, though the range across individuals is wide.
Because it can only be confirmed in hindsight, “menopause” as a lived experience actually describes the final stretch of late perimenopause leading up to that 12-month mark. This is one reason people frequently describe feeling “in menopause” for a period of time, even though clinically the term refers to a single retrospective date.
Stage 4: Early Postmenopause – The First Years After
Early postmenopause spans roughly the first several years following the final menstrual period. This stage is when many of the most disruptive vasomotor symptoms tend to peak or persist. Research from the Study of Women’s Health Across the Nation found that frequent hot flashes and night sweats lasted a median of several years across the full transition, with symptoms continuing for an average of roughly 4.5 years after the final period for many women (Avis et al., JAMA Internal Medicine, 2015).
This stage is also associated with measurable changes in bone metabolism. Longitudinal cohort data show that bone mineral density (BMD) loss accelerates during the late transition and early postmenopause, as declining estrogen reduces its protective effect on bone remodeling (Finkelstein et al., J Clin Endocrinol Metab, 2008). This is one reason baseline bone health assessment is often a meaningful part of a broader health check during this window.
Symptoms that tend to characterize early postmenopause include:
- Persistent or peak-intensity hot flashes and night sweats for many women
- Increased vaginal dryness and discomfort
- More noticeable urinary symptoms
- Accelerated bone density changes
- Gradual stabilization of mood for most women, though not universally
Stage 5: Late Postmenopause – Long-Term Health Considerations
Late postmenopause refers to the years and decades following the initial postmenopausal transition. For many women, the acute vasomotor symptoms that dominated perimenopause and early postmenopause gradually ease. However, other changes tend to persist or even progress.
Genitourinary syndrome of menopause (GSM)-a cluster of symptoms including vaginal dryness, irritation, and urinary changes caused by declining estrogen’s effect on genital and urinary tissue-is one notable exception to the general pattern of symptoms fading over time. Clinical literature describes GSM as a condition that, unlike hot flashes, tends to persist and can gradually worsen without attention, rather than naturally resolving (Gandhi et al., American Journal of Obstetrics & Gynecology, 2016).
Long-term postmenopausal health considerations that specialists often monitor include:
- Continued bone density surveillance, given cumulative loss over the transition
- Cardiovascular risk factor monitoring, since estrogen’s cardioprotective influence diminishes
- Ongoing evaluation and, where appropriate, management of genitourinary symptoms
- General metabolic and hormonal health tracking as part of routine, proactive care
Why Hormone Testing and Baseline Data Can Help Pinpoint Your Stage
Because the menopause transition is defined largely by patterns over time rather than a single measurement, many specialists favor an approach that combines menstrual history, symptom tracking, and periodic hormone assessment. This is where comprehensive, evidence-based diagnostics can offer real clarity. Establishing a personal a specialist hormone evaluation profile earlier in the transition-covering markers like FSH, estradiol, and AMH trends-can give both patient and specialist a clearer reference point for interpreting changes as they unfold, rather than trying to reconstruct the picture after symptoms have already become disruptive.
Symptoms That Can Overlap Across Stages
While certain symptoms cluster more heavily in specific stages, several can appear at almost any point in the transition and vary widely between individuals:
- Hot flashes and night sweats (vasomotor symptoms)
- Sleep disturbance, independent of night sweats
- Mood changes, including increased anxiety or depressive symptoms
- Vaginal dryness and changes in sexual comfort
- Urinary frequency or urgency
- Joint aches or new body composition changes
- Brain fog or subjective memory changes
Because these symptoms overlap so heavily across stages, tracking the pattern and timing of menstrual cycles alongside symptoms tends to be more informative for staging purposes than symptoms alone.
When to Talk to a Specialist
Because hormone fluctuations during the menopause transition are not linear, self-diagnosing an exact stage from symptoms alone can be difficult and, at times, misleading. A specialist can help interpret your menstrual history, symptom pattern, and relevant lab markers together, and can also rule out other conditions-such as thyroid dysfunction-that can mimic menopausal symptoms.
If symptoms are affecting daily functioning, sleep, mood, or quality of life at any stage of the transition, that is generally considered a reasonable point to seek a specialist evaluation rather than waiting for symptoms to resolve on their own.
Key Takeaways
- The different stages of menopause are formally organized by the STRAW+10 framework into perimenopause (early and late), menopause, and postmenopause (early and late) (Harlow et al., J Clin Endocrinol Metab, 2012).
- Menopause itself is a single retrospective date: 12 consecutive months without a period, occurring on average around age 51-52 (NAMS 2022 Position Statement, Menopause, 2022).
- Early menopause stages often begin with subtle menstrual cycle length changes before more classic symptoms like hot flashes appear.
- Vasomotor symptoms can persist for a median of several years and continue well into early postmenopause for many women (Avis et al., JAMA Internal Medicine, 2015).
- Bone density loss tends to accelerate in the late transition and early postmenopause, making this a meaningful window for baseline health assessment (Finkelstein et al., J Clin Endocrinol Metab, 2008).
- Perimenopause is associated with a measurably higher risk of depressive symptoms compared with premenopause, while that elevated risk does not appear to persist into postmenopause (Badawy et al., Journal of Affective Disorders, 2024).
- Unlike hot flashes, genitourinary symptoms tend to persist or worsen in postmenopause rather than fading with time (Gandhi et al., Am J Obstet Gynecol, 2016).
Frequently Asked Questions
The early stages of menopause-clinically referred to as early perimenopause-typically begin with subtle changes in menstrual cycle length, often a shift of seven or more days compared to a woman’s usual pattern. Mild sleep disruption, occasional hot flashes, and shifts in premenstrual mood sensitivity often accompany this stage as ovarian hormone production begins to fluctuate.
Using the STRAW+10 framework, there are three overarching menopause stages-perimenopause, menopause, and postmenopause-with perimenopause and postmenopause each further divided into early and late sub-stages, for five practical phases in total (Harlow et al., J Clin Endocrinol Metab, 2012).
A single hormone test rarely provides a definitive answer, since levels like FSH and estradiol fluctuate considerably during the transition rather than declining steadily. Trends in markers such as AMH over time, combined with menstrual history and symptoms, tend to offer more clarity than any one isolated result (Nelson et al., Human Reproduction Update, 2023).
Research following women over more than a decade found that frequent hot flashes and night sweats lasted a median of several years for many women, with symptoms persisting an average of roughly 4.5 years after the final menstrual period in some cases (Avis et al., JAMA Internal Medicine, 2015).
Research indicates perimenopause is associated with a meaningfully higher likelihood of depressive symptoms compared with the premenopausal years, though this elevated risk does not appear to extend into postmenopause for most women (Badawy et al., Journal of Affective Disorders, 2024). Persistent low mood is still worth discussing with a specialist rather than assuming it will resolve on its own.
Yes-longitudinal research shows bone mineral density loss tends to accelerate specifically during the late transition and early postmenopause as estrogen’s protective effect on bone remodeling declines (Finkelstein et al., J Clin Endocrinol Metab, 2008). This makes baseline bone health data particularly useful heading into this window.
Not uniformly. Vasomotor symptoms like hot flashes tend to ease for most women over time, but genitourinary symptoms-such as vaginal dryness and urinary changes-tend to persist or gradually worsen in postmenopause rather than resolving on their own (Gandhi et al., Am J Obstet Gynecol, 2016).
A Cochrane systematic review of randomized trials found that phytoestrogen supplements had only modest and inconsistent effects on hot flash frequency compared with placebo (Lethaby et al., Cochrane Database of Systematic Reviews, 2013). Discussing evidence-based options with a specialist is generally a more reliable approach than self-directed supplementation.
Timing varies considerably between individuals, but early perimenopause often begins in the mid-to-late 40s for many women, with menopause itself occurring, on average, around age 51 to 52 in the United States (NAMS 2022 Position Statement, Menopause, 2022). Genetics, health history, and other individual factors can shift this timeline earlier or later.
Curious where you fall along the transition? Explore UBERDOC’s menopause specialist services to connect directly with a specialist who can help interpret your symptoms and lab markers.
References
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 2012; 97(4):1159-1168. DOI: https://doi.org/10.1210/jc.2011-3362
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022; 29(7):767-794. DOI: https://doi.org/10.1097/GME.0000000000002028
- Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2015; 100(11):3975-4011. DOI: https://doi.org/10.1210/jc.2015-2236
- Avis NE, Crawford SL, Green R, et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine, 2015; 175(4):531-539. DOI: https://doi.org/10.1001/jamainternmed.2014.8063
- Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews, 2013; Issue 12, Art. No. CD001395. DOI: https://doi.org/10.1002/14651858.CD001395.pub4
- Nelson SM, Davis SR, Kalantaridou S, Lumsden MA, Panay N, Anderson RA. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update, 2023; 29(3):327-346. DOI: https://doi.org/10.1093/humupd/dmac045
- Finkelstein JS, Brockwell SE, Mehta V, et al. Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women. Journal of Clinical Endocrinology & Metabolism, 2008; 93(3):861-868. DOI: https://doi.org/10.1210/jc.2007-1876
- Badawy Y, Spector A, Li Z, Desai R. The risk of depression in the menopausal stages: A systematic review and meta-analysis. Journal of Affective Disorders, 2024; 357:126-133. DOI: https://doi.org/10.1016/j.jad.2024.04.041
- Gandhi J, Chen A, Dagur G, Smith N, Cali V. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American Journal of Obstetrics & Gynecology, 2016; 215(6):704-711. DOI: https://doi.org/10.1016/j.ajog.2016.07.045
Ready to talk to
a specialist?
Skip the wait, the paperwork, and the referrals.
A certified specialist is ready to see you.
